GLOSTRUP, DENMARK--(Marketwire - March 21, 2011) - Dako Denmark A/S and the Rabbit
Monoclonal Antibody Company, Epitomics, Inc.,
announced today that they have entered into a collaboration which will
companies to unite competencies to provide the Anatomic Pathology market
"Dako is on a mission to fight cancer. We are therefore very pleased to
this strategic alliance that will combine the competencies of Dako and
to establish the optimal portfolio of very high quality rabbit monoclonal
antibodies to be used in diagnosing cancer and in developing predictive
to the benefit of cancer patients all over the world," says Lars Holmkvist,
of Dako Denmark A/S.
"The strategic alliance with Dako is an important endorsement of RabMAbs in
field of immunohistochemistry (IHC) for anatomic pathology - a rapidly
market. In recent years Epitomics has accumulated a collection of companion
diagnostics antibodies in the field of pathology. This alliance will take
the next level," says Dr. Guo-Liang Yu, President and CEO of Epitomics,
Dako's expertise within the field of human cancer diagnostics, including
development of new diagnostic antibodies relevant in identifying,
differentiating and characterizing tumors, and Epitomics' exclusive
property rights and expertise within development and production of rabbit
monoclonal antibodies are the key ingredients to future development of
diagnostics, prognostics and predictive immunohistochemical assays, also
as companion diagnostics or PharmacoDiagnostics (PharmDxTM).
"The exploitation of Dako's market-leading approach in supplying automated
system solutions within diagnostic immunohistochemistry, and Epitomics'
technical superiority within generation of rabbit monoclonal antibodies
bring new and previously unseen high-quality diagnostic tools to the
pathology community," says Lars Holmkvist.
Besides the development and launch of new state-of-the-art monoclonal
the strategic alliance between Dako and Epitomics also includes a
transfer from Epitomic's to Dako's facilities.
The financial terms of the agreement were not disclosed.
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1,000 people and being present in more than 80 countries, Dako covers
essentially all of the anatomic pathology markets globally. Dako is owned
private equity fund, EQT. www.dako.com
Epitomics, Inc., an emerging biotechnology company, is dedicated to
breakthrough monoclonal antibody technology for research, diagnostic and
therapeutic applications. The company utilizes a unique and proprietary
(Rabbit Monoclonal Antibody) technology which produces antibodies with
binding affinity and bioactivity in a wide variety of biological assays.
Epitomics, Inc. is headquartered in Burlingame, California, and operates a
wholly owned subsidiary in Hangzhou, the People's Republic of China.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE